Literature DB >> 24613782

Tim-1 blockade with RMT1-10 increases T regulatory cells and prolongs the survival of high-risk corneal allografts in mice.

Xiaobo Tan1, Ying Jie2, Yingnan Zhang2, Yi Qin2, Qing Xu2, Zhiqiang Pan3.   

Abstract

Anti-Tim-1 monoclonal antibody (mAb) RMT1-10 is effective in promoting allograft survival through blocking Tim-1. However, its role in corneal transplantation is unclear. This study aims to evaluate the effect of RMT1-10 on high-risk corneal transplantation. BALB/c mice were transplanted with corneal grafts from C57BL/6 mice and intraperitoneally injected with RMT1-10 or isotype IgG. The transparency of corneal graft was evaluated by slit lamp biomicroscopy. Flow cytometry was used to determine the phenotype of CD4(+) T cells, including CD154, Tim-3, CD25 and Foxp3, and to analyze the proliferation capacity of CD4(+) T cells and the suppressive capacity of T regulatory (Treg) cells. The levels of interferon-gamma (IFN-γ), IL-4 and transforming growth factor-beta1 (TGF-β1) were investigated by intracellular staining and/or ELISA assay. The delayed-type hypersensitivity (DTH) response was evaluated by ear swelling assay. RMT1-10 therapy delayed the onset of rejection and significantly prolonged the survival of corneal allograft. In RMT1-10 treated mice, percentages of CD4(+)CD154(+) cells and CD4(+)Tim-3(+) cells were significantly decreased while the frequency of CD4(+)CD25(+)Foxp3(+) Treg cells was significantly up-regulated, compared with those of isotype IgG treated mice. And, in vitro proliferation of CD4(+) T cells was significantly inhibited by RMT1-10. In addition, percentage of intracellular expression of IFN-γ and IL-4 in CD4(+) T cells isolated from RMT1-10 treated mice was significantly reduced. After co-culturing with RMT1-10 in vitro, CD4(+) T cells produced significantly decreased levels of IFN-γ and IL-4 and significantly increased levels of TGF-β1. Furthermore, RMT1-10 inhibited DTH response of recipient mice and enhanced the suppressive capacity of Treg cells isolated from RMT1-10 treated mice. Our data indicate that Tim-1 blockade with RMT1-10 could suppress immunological rejection and prolong the survival of corneal allograft through regulating T cell responses.
Copyright © 2014 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  T regulatory cells; Tim-1; high-risk corneal allograft rejection; mice

Mesh:

Substances:

Year:  2014        PMID: 24613782     DOI: 10.1016/j.exer.2014.02.019

Source DB:  PubMed          Journal:  Exp Eye Res        ISSN: 0014-4835            Impact factor:   3.467


  7 in total

Review 1.  Therapeutic approaches for induction of tolerance and immune quiescence in corneal allotransplantation.

Authors:  Maryam Tahvildari; Afsaneh Amouzegar; William Foulsham; Reza Dana
Journal:  Cell Mol Life Sci       Date:  2018-01-06       Impact factor: 9.261

Review 2.  Blocking monoclonal antibodies of TIM proteins as orchestrators of anti-tumor immune response.

Authors:  Muhammad Baghdadi; Shintaro Takeuchi; Haruka Wada; Ken-Ichiro Seino
Journal:  MAbs       Date:  2014-10-30       Impact factor: 5.857

3.  Knockdown of T Cell Immunoglobulin and Mucin 1 (Tim-1) Suppresses Glioma Progression Through Inhibition of the Cytokine-PI3K/AKT Pathway.

Authors:  Peng Zhou; Maoxing Fei; Yanling Han; Mengliang Zhou; Handong Wang
Journal:  Onco Targets Ther       Date:  2020-08-04       Impact factor: 4.147

4.  TIM-1 serves as a receptor for Ebola virus in vivo, enhancing viremia and pathogenesis.

Authors:  Bethany Brunton; Kai Rogers; Elisabeth K Phillips; Rachel B Brouillette; Ruayda Bouls; Noah S Butler; Wendy Maury
Journal:  PLoS Negl Trop Dis       Date:  2019-06-26

Review 5.  Corneal Allografts: Factors for and against Acceptance.

Authors:  Justyna Sakowska; Paulina Glasner; Maciej Zieliński; Piotr Trzonkowski; Leopold Glasner
Journal:  J Immunol Res       Date:  2021-10-03       Impact factor: 4.818

Review 6.  Tolerogenic Dendritic Cells on Transplantation: Immunotherapy Based on Second Signal Blockage.

Authors:  Priscila de Matos Silva; Julia Bier; Lisiery Negrini Paiatto; Cassia Galdino Albuquerque; Caique Lopes Souza; Luis Gustavo Romani Fernandes; Wirla Maria da Silva Cunha Tamashiro; Patricia Ucelli Simioni
Journal:  J Immunol Res       Date:  2015-10-12       Impact factor: 4.818

7.  Anti-TIM-1 Monoclonal Antibody (RMT1-10) Attenuates Atherosclerosis By Expanding IgM-producing B1a Cells.

Authors:  Hamid Hosseini; Li Yi; Peter Kanellakis; Anh Cao; Christopher Tay; Karlheinz Peter; Alex Bobik; Ban-Hock Toh; Tin Kyaw
Journal:  J Am Heart Assoc       Date:  2018-06-23       Impact factor: 5.501

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.